Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting
Top Cited Papers
- 1 January 2010
- journal article
- practice guideline
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 103 (01) , 13-28
- https://doi.org/10.1160/th09-08-0580
Abstract
There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/ or stent thrombosis, and the risk of bleeding. This consensus document comprehensively reviews the published evidence and presents a consensus statement on a ‘best practice’ antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients.Keywords
This publication has 89 references indexed in Scilit:
- The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial managementEP Europace, 2008
- Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary interventionEuropean Heart Journal, 2008
- Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial FibrillationStroke, 2008
- Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and ClopidogrelThe Journal of Clinical Pharmacology, 2008
- Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the CRUSADE registryAmerican Heart Journal, 2007
- Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approachEuropean Heart Journal, 2007
- Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohortAmerican Heart Journal, 2007
- Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trialAmerican Heart Journal, 2006
- Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulationAmerican Heart Journal, 2004
- Atrial Fibrillation and the Hypercoagulable State: From Basic Science to Clinical PracticePathophysiology of Haemostasis and Thrombosis, 2003